Roche Tecentriq Extends Life in Lung Cancer Study

Dec 07, 2017

Wall Street Journal

Roche Holding’s immunotherapy drug, already approved for advanced bladder cancer, may help lung cancer patients live longer, according to a late-stage study.

The drugmaker reported that patients taking Tecentriq, along with Roche’s older cancer drug Avastin and chemotherapy, showed a 38 percent reduced risk of their disease worsening, compared with patients who were given only Avastin and chemotherapy.

Widening the market for Tecentriq would be a big win for Roche, as the company continues to struggle with patent loss and biosimilar competition.

Read the WSJ coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments